Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...
The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday. As the first Bruton's tyrosine kinase (BTK) inhibitor ...
Hone Health reports that doctors are reconsidering hormone therapy for breast cancer survivors, suggesting safe options may exist despite previous guidelines.
Egypt’s efforts to build up its economy and boost exports after a grueling crisis may be getting help from an unexpected industry: dietary supplements. Local manufacturing of vitamin- and mineral-rich ...
1State University of New York at Buffalo, Buffalo, NY.
The FDA has approved the use of Eli Lilly’s imlunestrant, now to carry the brand name Inluriyo, as a second-line treatment for patients with certain types of breast cancer. The drug’s label doesn’t ...
Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD). Like the first oral SERD, Lilly’s imlunestrant is only cleared to treat ER-positive, HER2-negative ...
Ribociclib plus nonsteroidal aromatase inhibitor therapy reduces the risk for invasive disease recurrence by 28.5% compared with nonsteroidal aromatase inhibitor ...
Inluriyo is approved for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after prior endocrine therapy failure. The EMBER-3 trial showed Inluriyo reduced cancer progression or death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback